On February 23, 2026, Protara Therapeutics, Inc. announced positive interim data from its ongoing Phase 2 trial of TARA-002 for non-muscle invasive bladder cancer, showing a 65.7% complete response rate in BCG-Unresponsive patients and 72.4% in BCG-Naïve patients with no serious treatment-related side effects reported.